Autopsy report · NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Cause of deathFunding or business
“Lack of funding”
Life of this trial
- Ran for about 5 years 10 months before it stopped.
- 20 participants enrolled.
- Results were posted on the registry 2 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Interventions
- brentuximab vedotin; rituximab; laboratory biomarker analysis
- Participants
- 20
- Sites
- 3
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.